BeOne Medicines Ltd.
ONCDrugs in Pipeline
10
Phase 3 Programs
8
Upcoming Catalysts
6
Next Catalyst
Jul 15, 2026
13wMarket Overview
Stock performance and key metrics
6 upcoming, 0 past
Tislelizumab
Advanced Malignancies
Venetoclax
CLL
BGB-16673
B-cell Malignancy
Tacrolimus
Primary Membranous Nephropathy
Subcutaneous Tislelizumab
Metastatic Gastric Adenocarcinoma
Pirtobrutinib
Chronic Lymphocytic Leukemia
Bendamustine
CLL
Sonrotoclax
Mantle Cell Lymphoma
Dexamethasone
Relapsed/Refractory Multiple Myeloma
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tislelizumab | Phase 3 | Advanced Malignancies | - | - |
Venetoclax | Phase 3 | CLL | - | - |
BGB-16673 | Phase 3 | B-cell Malignancy | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma | - | - |
Pirtobrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Bendamustine | Phase 3 | CLL | - | - |
Sonrotoclax | Phase 3 | Mantle Cell Lymphoma | - | - |
Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |